Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis

a technology of spironolactone and composition, which is applied in the field of composition comprising spironolactone for the treatment of multiple sclerosis, can solve the problems of high complexity and discomfort of its application, and many ms patients do not respond in a favorable way

a technology of spironolactone and composition, which is applied in the field of composition comprising spironolactone for the treatment of multiple sclerosis, can solve the problems of high complexity and discomfort of its application, and many ms patients do not respond in a favorable way

US20130203719A1Inactive Publication Date: 2013-08-08PONTIFISIA UNIVERSIDAD KATOLIKA DE CHILE
0 Cites 4 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis
  • Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis
  • Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012]The present invention is based in the determination of a therapeutic effect of a composition comprising spironolactone that was not previously described. Spironolactone is a synthetic steroid with a structure similar to aldosterone.

[0013]Spironolactone binds to the mineralocorticoid receptor (MR) inhibiting competitively the action of aldosterone, which is why it has been used for over 40 years for the treatment of hyperaldosteroinism. For the same reason it has been used for inhibiting the pathophysiological action of aldosterone in cardiac failure (Pitt et al. 1999. The New England Journal of Medicine, 341 (10): 709-717).

[0014]The objective in determining if a composition of spironolactone would have an effect in the development of MS is based on the results obtained from a research from our group, relating to the mechanism of action of aldosterone for generating hypertension and cardiovascular disease (Herrada et al. 2010. Journal of Immunology, 184, 191-202). Aldosterone i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and / or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

Description

FIELD OF INVENTION[0001]The present invention relates to the use of a composition comprising spironolactone for the treatment of multiple sclerosis.BACKGROUND OF THE INVENTION[0002]Multiple Sclerosis (MS) is one of the most common neurological disorders worldwide and one of the major neurological non-traumatic disability causes in young adults, more common in women than men, the first symptoms appearing around 30 years of age. Multiple sclerosis is a progressive disease, of autoimmune inflammatory origin, characterized by the loss or damage of myelin sheath coating nervous fibers of the Central Nervous System (CNS), which is substituted with connective tissue plaques. This generates an alteration in conduction of nervous impulse and said alteration is the source of the most common symptoms of the disease, such as muscular weakness, spasticity or motor dysfunction, visual alterations, equilibrium problems, urinary dysfunction, constipation, and cognitive or behavioral anomalies (Atla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
08 Aug 2013
Publication
US20130203719A1
IPC
A61K31/585
CPC
A61K31/585; A61P21/00; A61P25/00; A61P25/28
Inventors
KALERGIS, ALEXIS M.; HERRADA, ANDRES A.